Researchers can detect ‘toxic’ small aggregates of a particular protein in the blood of individuals with Alzheimer’s disease, as well as in individuals who showed no signs of cognitive impairment at the time the blood sample was taken, but who developed it at a later date. This blood test picks up oligomers — or small, misfolded aggregates — of the amyloid beta protein, which scientists believe triggers the development of Alzheimer’s.
